Prescription for Better Access podcast

Understanding ICER's Second Annual Launch Price and Access Report

0:00
42:20
Rewind 15 seconds
Fast Forward 15 seconds

In this episode, we welcome back Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), to discuss an exciting new development in the industry: the release of ICER’s second annual Launch Price and Access Report. We dig into the report’s findings and explore why median net launch prices have climbed over the past several years, what the data show about delays and cost sharing for patients trying to get newly approved drugs, and what manufacturers, payers, and employers could do differently. Sarah makes the case for a voluntary de-escalation, with prices set in line with value and met by streamlined access. We also explore the role of purchasers, her call for a federally funded consortium of independent assessment groups, and her concerns about MFN.

 

Questions or comments? Email [email protected]. Find us on X, LinkedIn, YouTube, and Threads.

More episodes from "Prescription for Better Access"